PharmTech Drug Digest 11.20
News|Videos|November 17, 2026

Challenges in Oral Delivery of Peptides: Bioavailability

Robert Sciscento, a senior scientist at Alcami Corporation, discusses formulation and delivery systems for oral peptides that might fix bioavailability challenges.

Oral peptide delivery has become a focus of developers moving into the peptide therapeutic market, especially those developing glucagon-like peptide-1 (GLP-1) products. However, these products often suffer from poor oral bioavailability.1 PharmTech spoke with Robert Sciscento, a senior scientist at Alcami Corporation, to find out more about formulation strategies for improving the oral bioavailability of peptides.

Sciscento describes 3 technologies for improving bioavailability. The first is polymethacrylate coatings, such as the Acryl-EZE and EUDRAGIT series. These coatings give enteric protection, so the drug isn’t released in the stomach, and they can release it at chosen pH regions of the gastrointestinal (GI) tract, he explains. For peptides, he says, this targeted delivery can be the difference between zero bioavailability and a meaningful increase.

The second approach is self-emulsifying drug delivery systems (SEDDS). A matrix of oil, surfactant, and cosolvent can raise a peptide’s bioavailability. Many formulators already know the format from the softgel industry and from work on BCS Class II and IV compounds. To make a solid SEDDS, a matrix that dissolves the active ingredient is loaded onto a highly porous carrier such as microcrystalline cellulose. The loaded carrier is then pressed into tablets or filled into capsules.

The third and most complex strategy is solid dispersion. Here the peptide is held in a polymer matrix that protects it from breaking down in the stomach and elsewhere in the GI tract, Sciscento explains. The choice of polymer can improve both solubility and stability. He states that Soluplus, an amphiphilic graft copolymer, is an option for doing both.

Sciscento also points to sodium N-[8-(2-hydroxybenzoyl)amino] caprylate (SNAC), a permeation enhancer best known from Rybelsus (oral semaglutide) tablets. SNAC is an industry-proven benchmark, but it usually has to be used in large amounts. A 3mg peptide dose, for example, may need 300 to 500 mg of SNAC, he explains. The resulting large tablets can make patients less likely to take them as prescribed. SNAC tablets also have strict dosing rules: they must be taken on an empty stomach with very little water. If patients don’t follow those rules, the tablet wont work as well.

Reference

  1. Challener C. Improving oral peptide delivery through structural modifications. PharmTech.com. November 2, 2026. https://www.pharmtech.com/view/improving-oral-peptide-delivery-through-structural-modifications

About the Speaker

Bobby Sciscento works at Alcami Corporation’s OSD facility located in Wilmington, NC as a Sr Scientist, Formulations. He holds a Master’s degree in Pharmaceutical Science from Campbell University. He has worked at Alcami for 5 years and in oral solid dose formulation development for 11 years. Bobby has supported multiple successful first in human IND applications and maintains a working knowledge of applying various drug development techniques to scalable industrial based formulations.


Related to this article